Systematic Review And Meta-Analysis Of Psoriasis Treatments.

• ClinicalTrials.gov Identifier: NCT01425138
• Recruitment Status: Completed
• First Posted: August 29, 2011
• Last Update Posted: December 3, 2018
• Sponsor: Pfizer
• Collaborator: University of Connecticut School of Pharmacy and Hartford Hospital
• Information provided by (Responsible Party): Pfizer

Tracking Information

• First Submitted Date: August 26, 2011
• First Posted Date: August 29, 2011
• Last Update Posted Date: December 3, 2018
• Study Start Date: June 2009
• Actual Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 26, 2011)

• Physician Global Assessment (PGA)
• Dermatology Life Quality Index (DLQI)
• Short-Form 36 (SF-36)

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures (submitted: September 20, 2011): No secondary outcomes [ Time Frame: No secondary outcomes ]
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Systematic Review And Meta-Analysis Of Psoriasis Treatments.
• Official Title: Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis
• Brief Summary: This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.
• Detailed Description: This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.
• Study Type: Observational
• Study Design: Observational Model: Other; Time Perspective: Retrospective
• Target Follow-Up Duration: Not Provided
• Biospecimen: Not Provided
• Sampling Method: Non-Probability Sample
• Study Population: Moderate-to-severe plaque psoriasis published trials.
• Condition: Psoriasis
• Intervention: Not Provided

Study Groups/Cohorts

Psoriasis

Published data on moderate-to-severe plaque psoriasis.

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: November 29, 2018): 1
• Original Estimated Enrollment (submitted: August 26, 2011): 0
• Actual Study Completion Date: June 2011
• Actual Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
• Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

• Trials that did not report the Physician's Global Assessment (PGA),
• Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT01425138
• Other Study ID Numbers: A3921142
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Pfizer
• Study Sponsor: Pfizer
• Collaborators: University of Connecticut School of Pharmacy and Hartford Hospital

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

• PRS Account: Pfizer
• Verification Date: November 2018